ACM
AMLX icon

ADAR1 Capital Management’s Amylyx Pharmaceuticals AMLX Stock Holding History

ADAR1 Capital Management’s Portfolio AMLX Stock Details AMLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$8.88M Sell
494,378
-506,226
-51% -$7.83M 0.41% 58
2026
Q1 		$13.9M Buy
1,000,604
+110,248
+12% +$1.55M 0.82% 27
2025
Q4 		$10.8M Buy
890,356
+24,154
+3% +$328K 0.79% 32
2025
Q3 		$11.8M Sell
866,202
-338,899
-28% -$3.19M 1.11% 19
2025
Q2 		$7.72M Sell
1,205,101
-266,486
-18% -$1.3M 1.18% 23
2025
Q1 		$5.21M Buy
+1,471,587
New +$5.24M 0.97% 31
2024
Q4 		– Sell
-220,906
Closed -$1.04M – 220
2024
Q3 		$716K Buy
220,906
+113,600
+106% +$255K 0.12% 98
2024
Q2 		$204K Buy
107,306
+68,448
+176% +$133K 0.04% 142
2024
Q1 		$110K Sell
38,858
-38,700
-50% -$506K 0.03% 144
2023
Q4 		$1.14M Buy
+77,558
New +$1.19M 0.41% 43

Other funds holding AMLX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
SVCM
Saturn V Capital Management Austin, Texas $697M AUM 628.57% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

ADAR1 Capital Management's AMLX Position: Q2 2026 in Review

ADAR1 Capital Management reduced its Amylyx Pharmaceuticals (AMLX) stake by 51% in Q2 2026, selling an estimated $7.83M and leaving 494,378 shares worth $8.88M. The position accounts for 0.41% of the portfolio, ranked #58.

ADAR1 Capital Management first reported a position in AMLX in Q4 2023 and has held it in 10 quarters since. The position peaked at $13.9M in Q1 2026. 206 funds tracked by Wall St. Rank hold AMLX as of Q2 2026.

  • ADAR1 Capital Management held 494,378 shares of Amylyx Pharmaceuticals worth $8.88M as of Q2 2026.
  • ADAR1 Capital Management sold 506,226 Amylyx Pharmaceuticals shares in Q2 2026, an estimated $7.83M.
  • Amylyx Pharmaceuticals made up 0.41% of ADAR1 Capital Management's portfolio in Q2 2026, its #58 holding.
  • ADAR1 Capital Management first reported a position in Amylyx Pharmaceuticals in Q4 2023 and has held it in 10 quarters since.
  • ADAR1 Capital Management's Amylyx Pharmaceuticals position peaked at $13.9M in Q1 2026.
  • 206 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q2 2026.

Based on ADAR1 Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.